6657 — Energenesis Biomedical Co Share Price
Last trade - 00:00- TWD3.91bn
- TWD3.29bn
- TWD7.16m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.38 | ||
| Price to Tang. Book | 5.54 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 576.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.5% | ||
| Return on Equity | -24.4% | ||
| Operating Margin | -3174.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | TWDm | 6.25 | 7.08 | 7.49 | 7.35 | 7.16 | n/a | n/a | 9.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- August 28th, 2012
- Public Since
- August 8th, 2018
- No. of Shareholders
- 4,907
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Taiwan Stock Exchange
- Shares in Issue
- 76,224,000
- Address
- 6F-3, No.21, Lane 583, Ruiguang Road, TAIPEI, 114
- Web
- http://www.energenesis-biomedical.com/
- Phone
- +886 226270835
- Contact
- Ming-tsan Chiang
- Auditors
- Deloitte & Touche LLP
Upcoming Events for 6657
Similar to 6657
Abnova Taiwan
Taiwan Stock Exchange
Applied BioCode
Taiwan Stock Exchange
Kim Forest Enterprise Co
Taiwan Stock Exchange
PHARMAESSENTIA
Taiwan Stock Exchange
Pell Bio Med Technology Co
Taiwan Stock Exchange
FAQ
As of Today at 20:27 UTC, shares in Energenesis Biomedical Co are trading at TWD51.30. This share price information is delayed by 15 minutes.
Shares in Energenesis Biomedical Co last closed at TWD51.30 and the price had moved by -16.86% over the past 365 days. In terms of relative price strength the Energenesis Biomedical Co share price has underperformed the FTSE Developed Asia Pacific Index by -22.95% over the past year.
There is no consensus recommendation for this security.
Find out moreEnergenesis Biomedical Co does not currently pay a dividend.
Energenesis Biomedical Co does not currently pay a dividend.
Energenesis Biomedical Co does not currently pay a dividend.
To buy shares in Energenesis Biomedical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of TWD51.30, shares in Energenesis Biomedical Co had a market capitalisation of TWD3.91bn.
Here are the trading details for Energenesis Biomedical Co:
- Country of listing: Taiwan
- Exchange: TAI
- Ticker Symbol: 6657
Based on an overall assessment of its quality, value and momentum Energenesis Biomedical Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Energenesis Biomedical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -11.69%.
As of the last closing price of TWD51.30, shares in Energenesis Biomedical Co were trading -10.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Energenesis Biomedical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at TWD51.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Energenesis Biomedical Co's directors